Navigation Links
Hebrew University professor's work leads to FDA approval for product
Date:3/26/2009

Jerusalem, March 25, 2009 A material developed at the Hebrew University of Jerusalem that is designed to prevent adhesions (scar tissue) following surgery has led to approval by the U.S. Food and Drug Administration (FDA) of a product for use in pediatric cardiac surgery patients.

The product is the result of Prof. Daniel Cohn's invention of novel, tailor-made, biodegradable polymers for the prevention of post-surgical adhesions. SyntheMed Inc. of Iselin, N.J. in the U.S., received the technology from Yissum the Technology Transfer Company of the Hebrew University, and has now obtained FDA pre-market approval for the first product, REPEL-CV Adhesion Barrier, for use in pediatric patients (21 and younger) who are likely to need secondary open heart surgery.

The generation of adhesions following heart surgery is of special concern, since they may affect cardiac function. Furthermore, in the frequent cases where repeat operations are required, adhesions obscure cardiac landmarks, making the procedure potentially life-threatening to the patient due to inadvertent vascular or cardiac injury.

In the U.S., there are 350,000 to 400,000 children with congenital cardiac abnormalities. Many neonatal and infant patients must undergo multiple surgeries before their defect is corrected, while other children require additional operations as they grow. The REPEL-CV Adhesion Barrier product gives physicians another tool to help decrease the complications that may occur during these surgeries. .

"I am very excited that the long process that started several years ago in our laboratory at the Institute of Chemistry of the Hebrew University with the design and synthesis of a family of biodegradable polymers was recently approved by the FDA," said Prof. Cohn.

"This biomedical product harnessed the unique properties of a family of custom-made, biodegradable polymers aimed at treating a large, incredibly widespread clinical problem, which pertains to all surgeries: post-operative adhesions. Each and every surgery conducted inevitably results in post-surgical adhesions, and the polymeric film developed at the Hebrew University allows us to minimize those adhesions."

The approval by the FDA came after its approval in Europe and Canada.

Receiving the approval of the different regulatory agencies was the result of the work of a large team. It started with the research conducted by Prof. Cohn and his students, who largely contributed to this endeavour, and continued with the work done at SyntheMed Inc. that developed the product and brought it to the clinic.

"I would like to thank each and all of them and acknowledge their pivotal contribution to the success of this project, all along the journey," said Prof. Cohn.

Prof. Cohn's work on the polymers led to his receiving first prize last year in the Kaye Awards for Innovation, given annually to encourage faculty, staff, and students of the Hebrew University to develop innovative methods and inventions with good commercial potential.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Related biology news :

1. Hebrew University scientists reveal mechanism that triggers differentiation of embryo cells
2. Scent on demand: Hebrew University scientists enhance the scent of flowers
3. Hebrew University develops novel approach for treating mitochondrial disorders
4. Hebrew University study opening new route for combating viruses
5. Electronic structure of DNA revealed for 1st time by Hebrew University and collaborating researchers
6. Five young Hebrew University scientists win first competitive EU grants
7. Hebrew SeniorLife researchers search for aging, osteoporosis genes
8. Antioxidant to retard wrinkles discovered by Hebrew University researcher
9. The University of Miami receives grants from Royal Caribbean Cruises Ltd.s Ocean Fund
10. University researchers to develop coatings that kill superbugs
11. K-State researchers work with university in Ghana to create biofuels from native tree seeds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hebrew University professor's work leads to FDA approval for product
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: